Connect with us

Life Sciences

PathAI Diagnostics Unveils AI-Assisted Lab Test for MASLD and MASH

What You Should Know: PathAI Diagnostics, formerly Poplar Healthcare, a leading laboratory services company, today unveiled the world’s first AI-assisted…

Published

on

This article was originally published by HIT Consultant

What You Should Know:

  • PathAI Diagnostics, formerly Poplar Healthcare, a leading laboratory services company, today unveiled the world’s first AI-assisted laboratory-developed test for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
  • MASLD and MASH are posing an escalating healthcare challenge, affecting millions of individuals worldwide – as many as 37.8% of the global adult population suffers from some form of MASLD, a potential precursor to severe conditions such as cirrhosis and liver cancer. 

AI-Driven Tests for Improving MASLD/MASH Detection

While the gold standard for MASLD/MASH scoring is liver biopsy, the scoring provided by pathologists can exhibit variability. In fact, there can be as much as a 30% disagreement in MASH diagnosis between pathologists, and intra-observer variability can reach up to 41% for the same case. Accurate scoring and staging are paramount, as each fibrosis stage corresponds to approximately a two-fold increase in liver-related mortality. In response to this need, PathAI Diagnostics today announced AI.Dx MASH, a laboratory-developed test which provides AI-assisted histologic scoring that supports expert pathologists with enhanced insights for liver biopsy reporting.

In order to better tackle this growing issue, PathAI Diagnostics developed AI.Dx MASH, a laboratory developed test, which provides AI-assisted histologic scoring that supports expert pathologists with enhanced insights for liver biopsy reporting. “We are excited to bring the world’s first AI-assisted Laboratory Developed Test for MASH to market,” said Jim Sweeney, President of PathAI Diagnostics. “The tool uses our deep expertise in AI-powered pathology coupled with our world-class diagnostics laboratory to improve patient outcomes through AI-assisted histologic scoring for MASH.”

This groundbreaking tool utilizes an AI algorithm that has been proven to significantly reduce inter- and intra-operator variability in CRN scoring. Moreover, AI.Dx MASH reports include image overlays and quantitation, offering a comprehensive view of steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis, thus facilitating more accurate diagnosis and staging.8-11

diagnostics

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending